HRTX News and Press, Heron Therapeutics Inc. From 11/15/21

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Heron Therapeutics to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 11, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing be...

Heron Therapeutics, Inc. (HRTX) Q3 2021 Results Earnings Conference Call November 03, 2021, 04:15 PM ET Company Participants David Szekeres - Executive Vice President, Chief Operating Officer Barry Quart - Chief Executive Officer and Chairman of the Board John Poyhonen - President and Chief C...

Heron Therapeutics (NASDAQ:HRTX): Q3 GAAP EPS of -$0.51 beats by $0.10. Revenue of $23.23M (+16.3% Y/Y) misses by $2.28M. Shares -1.15%. Press Release As of September 30, 2021, Heron had cash, cash equivalents and short-term investments of $202.8 million, compared to $208.5 mil...

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF® net product sales of $2.1 million in its first quarter of launch with 160 unique accounts already purchasing ZYNRELEF an...

Heron Therapeutics (NASDAQ:HRTX) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, after market close. The consensus EPS Estimate is -$0.60 and the consensus Revenue Estimate is $25.51M (+27.7% Y/Y). In October, Seeking Alpha contributor Biologics believes that the...

Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021 PR Newswire SAN DIEGO , Oct. 28, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the ...

Biotech stocks can be volatile to the extreme. Former high-flying stocks can crash on a bad clinical outcome, regulatory review, or new competitor on the market. The interesting part, though, is that some former star biotech stocks can, on occasion, regain their momentum. Beaten-down biotec...

After setbacks with the FDA, Heron finally launched Zynrelef in July with a constricted label to market. I believe Zynrelef might struggle in its first few quarters on the market. Heron is looking to broaden Zynrelef’s label with supplementary studies. In addition, the company ...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...